Key Points
- Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals on June 2 at an average price of $3.68, totaling about $110,400. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Borgeson has also sold 30,000 shares each on May 5 and April 7, indicating a pattern of recent insider selling. After the latest transaction, he still held about 6.17 million shares.
- Recursion Pharmaceuticals recently reported a smaller-than-expected loss, posting EPS of -$0.22 versus the expected -$0.30, but revenue came in below estimates at $6.47 million. Analysts currently have a Hold consensus rating on the stock with an average target price of $8.10.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Namandje Bumpus sold 4,386 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $3.54, for a total value of $15,526.44. Following the completion of the transaction, the director owned 43,171 shares in the company, valued at approximately $152,825.34. The trade was a 9.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Recursion Pharmaceuticals Trading Up 9.5%
NASDAQ:RXRX opened at $3.80 on Friday. The stock's 50 day moving average price is $3.30 and its 200 day moving average price is $3.82. The company has a market capitalization of $2.01 billion, a PE ratio of -3.17 and a beta of 1.04. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 52-week low of $2.77 and a 52-week high of $7.18.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm's quarterly revenue was down 56.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.50) EPS. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.02 EPS for the current year.
Wall Street Analysts Forecast Growth
RXRX has been the topic of a number of research reports. Bank of America dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 25th. JPMorgan Chase & Co. dropped their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an "overweight" rating on the stock in a research note on Thursday, April 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Morgan Stanley lifted their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an "equal weight" rating in a research note on Thursday, May 14th. Finally, Wall Street Zen downgraded Recursion Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Recursion Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $8.10.
Get Our Latest Research Report on RXRX
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $31,000. Integral Investment Advisors Inc. purchased a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $39,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $41,000. MQS Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $41,000. Finally, Allworth Financial LP lifted its holdings in shares of Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company's stock valued at $47,000 after buying an additional 4,403 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
